Addex regains nasdaq listing compliance

Ad hoc announcement pursuant to art. 53 lr geneva, switzerland, november 8, 2023 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced it had received written notification from the nasdaq stock market llc (nasdaq) that it has regained compliance with the minimum bid price requirement of $1.00 per ads under nasdaq listing rule 5550(a)(2) and currently meets all other applicable criteria for continued listing.
ADXN Ratings Summary
ADXN Quant Ranking